23:38 , Jul 24, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Binding assays; cellular assays A screening method using non-coding SNPs from genome-wide association studies (GWAS) could help identify new drug targets. The method involves five steps: creating double-stranded 31-base pair DNA constructs with each GWAS-identified...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Clinical News

Nelipepimut-S: Phase III discontinued

Galena discontinued the double-blind, placebo-controlled, international Phase III PRESENT trial comparing intradermal NeuVax plus intradermal Leukine sargramostim vs. Leukine alone at an IDMC’s recommendation based on a planned interim futility analysis. Dr. Reddy’s has...
00:45 , Jun 30, 2016 |  BC Extra  |  Clinical News

Galena plummets after halting NeuVax study

Galena Biopharma Inc. (NASDAQ:GALE) lost $1.68 (83%) to $0.35 on Wednesday after it said it will halt the Phase III PRESENT study of NeuVax nelipepimut-S at an independent DMC's recommendation based on an interim futility...
07:00 , May 2, 2016 |  BC Week In Review  |  Clinical News

GALE-302: Additional Phase IIa data

Data from 17 HLA-A2-positive patients with endometrial or ovarian cancer who completed the Phase IIa portion evaluating 6 monthly injections of intradermal GALE-301 plus GM-CSF and continued to the booster series portion of an...
07:00 , May 2, 2016 |  BC Week In Review  |  Clinical News

FBP vaccine: Additional Phase IIa data

Data from 17 HLA-A2-positive patients with endometrial or ovarian cancer who completed the Phase IIa portion evaluating 6 monthly injections of intradermal GALE-301 plus GM-CSF and continued to the booster series portion of an open-label,...
07:00 , Jun 8, 2015 |  BC Week In Review  |  Clinical News

FBP vaccine: Additional Phase IIa data

Additional data from 51 HLA-A2-positive patients with endometrial or ovarian cancer in the Phase IIa portion of an open-label, U.S. Phase I/IIa trial showed that 6 monthly injections of 100, 500 or 1,000 ug intradermal...
08:00 , Nov 17, 2014 |  BC Week In Review  |  Clinical News

FBP vaccine: Preliminary Phase IIa data

Preliminary data from the Phase IIa portion of an open-label, U.S. Phase I/IIa trial in 51 patients with ovarian or endometrial cancer showed that 6 monthly injections of 100, 500 or 1,000 ug intradermal GALE-301...
07:00 , Aug 18, 2014 |  BC Week In Review  |  Clinical News

FBP vaccine: Preliminary Phase I data

Preliminary data from an open-label, dose-escalation, U.S. Phase I trial in 30 HLA-A2-positive patients with endometrial or ovarian cancer showed that no recurrences have been observed in patients in the optimal dose cohort of 1,000...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Clinical News

FBP vaccine: Completed Phase IIa enrollment

Galena completed enrollment of 45 HLA-A2-positive or HLA-A2-negative patients with ovarian or endometrial cancer in an open-label, U.S. Phase IIa trial evaluating 1,000 Ug intradermal GALE-301 plus GM-CSF. Patients will receive an initial induction series...
08:00 , Jan 13, 2014 |  BC Week In Review  |  Clinical News

GALE-301: Phase II started

Galena began an open-label, U.S. Phase II trial to evaluate GALE-301 plus GM-CSF in 30 HLA-A2-positive and 30 HLA-A2-negative patients with ovarian and endometrial cancer. Patients will receive an initial induction series of 6 vaccinations...